Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Precipio, Inc.

Get SEC filing alerts via email and in your feed for Precipio, Inc.

PRPO

Precipio, Inc.

About Precipio, Inc.

Precipio, Inc. is a healthcare biotechnology company specializing in cancer diagnostics. It develops and commercializes proprietary technologies and products, such as genetic panels and cell culture media, to improve diagnostic accuracy and reduce misdiagnoses in blood-related cancers. Operating CLIA-certified labs, it serves the U.S. oncology market with innovative, cost-effective solutions aimed at enhancing patient outcomes and laboratory efficiency.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Precipio, Inc.

1
1
Precipio, Inc. Precipio Reports 36% Revenue Growth to $6.7 Million in Q1 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Precipio, Inc. Precipio Reports 30% Revenue Growth to $24M for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Precipio, Inc. Precipio Reports 30% Revenue Growth to $6.8 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Precipio, Inc. Precipio Reports 27% Revenue Growth in Q2 2025, Achieves Net Income Improvement

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Precipio, Inc. Precipio Reports 44% Revenue Growth to $4.9 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Precipio, Inc. Precipio Reports $4.3 Million Net Loss and 22% Revenue Growth for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Precipio, Inc. Precipio Reports 15% Revenue Growth, Net Loss Reduction in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments